Charles River CEO predicts more manufacturers will spin off cell and gene therapy units
read at Endpoints ↗Neutral
Charles River Laboratories announced three months ago that it would divest its manufacturing unit dedicated to cell and gene therapy production.
CEO Birgit Girshick said the company expects it will not be the last manufacturer to separate such a unit, indicating that other firms may be evaluating similar moves.
The trend suggests a broader shift in the biotech sector toward focusing on core services or reducing capital‑intensive manufacturing, though details on timing or impact were not provided.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy”
read at Endpoints ↗103 words · retrieved Jun 3
comments(0)
5-min edit window · permanent after that